Literature DB >> 9755535

[Antihypertensive treatment. Prescription and cost of drugs. Survey in a tertiary care hospital].

D Akashi1, F K Issa, A C Pereira, A C Tannuri, D Q Fucciolo, M L Lobato, T G Galvão, I M Benseñor, P A Lotufo.   

Abstract

PURPOSE: To study the most prescribed anti-hypertensive drugs, evaluating their agreement with established guidelines and drug cost.
METHODS: One hundred and forty one (101 women, mean age = 53.3 years) hypertensive patients who searched spontaneous attention were interviewed in a tertiary-care hospital. The inclusion criteria were previous diagnosis of hypertension and non cardiovascular complaints.
RESULTS: The majority of the 107 (75.9%) patients were on medical treatment. In those receiving monotherapy, thiazides were the most utilized drugs, followed by methyldopa, ACE inhibitors, calcium channel-blockers, and beta-blockers. The association with thiazides (26.3%) followed the same preference. The second most prescribed drug, methyldopa, was the more expensive. Fifty percent of the patients purchased the drugs at their own expense.
CONCLUSION: A preference for prescription of expensive drugs for hypertension was detected in this sample in Brazil. This does not agree with major guidelines, mainly the V-JNC, which suggest thiazides and betablockers as first choice drugs for hypertensives with no complications or associated comorbidity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755535     DOI: 10.1590/s0066-782x1998000700010

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  1 in total

1.  Compliance with the Prescription of Antihypertensive Medications and Blood Pressure Control in Primary Care.

Authors:  Mayra Faria Novello; Maria Luiza Garcia Rosa; Ranier Tagarro Ferreira; Icaro Gusmão Nunes; Antonio José Lagoeiro Jorge; Dayse Mary da Silva Correia; Wolney de Andrade Martins; Evandro Tinoco Mesquita
Journal:  Arq Bras Cardiol       Date:  2017-02-13       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.